Young children with RS virus more likely to see general practitioner
A child coughing, suffering from rhinitis and shortness of breath? One third of children younger than 5 years who visit their GP with acute respiratory symptoms during the winter season test positive for the RS virus. This is according to the RSV ComNet study by Sarah Hak and team from UMC Utrecht, Nivel and RIVM, in collaboration with international partners, published in the Lancet Respiratory Medicine.
The study mapped the burden of disease of young children with RS virus infection in GPs. This burden of disease included disease progression, healthcare use and social impact, e.g. work absenteeism of parents or carers.
3414 children participated in the study, which took place in five European countries: Netherlands, Belgium, England, Spain and Italy. Of the participants, 331 children and their parents were from the Netherlands. Children with such an RS virus infection are sick for an average of 12 days and visit the GP an average of 2.4 times for this. Interestingly, the percentage of hospital admissions due to RS virus infections differs greatly between countries: in the Netherlands, 4% of children were admitted after the GP visit, while in Belgium it was as high as 44%.
Care utilisation for RS virus infections in young children differs between countries
Although the disease course of RS virus infection was similar between children, there were significant differences in healthcare utilisation. Children in the Netherlands visited the GP an average of 1.4 times, while in Spain it was 3.0 times. In addition, there were marked differences in medication prescribed by the GP because of the RS virus infection. In the Netherlands, 19% of children were prescribed antibiotics but not corticosteroids. In Italy, 32% of children were prescribed antibiotics. In both Italy and Spain, relatively high numbers of inhaled corticosteroids (25% and 9%, respectively) and oral corticosteroids (18% and 14%) were prescribed.
Infants were hospitalised more often (20.3%) than children aged between 1 and 5 years (6.7%). However, the duration of illness was similar. Babies with RS virus infections visited GPs an average of 2.7 times, slightly more often than children aged 1-5 years (2.1 times). Interestingly, GPs in Europe were more likely to prescribe medication to children aged 1-5 years (62%) than to babies (50%).
Parental absenteeism due to caring for their child
The survey shows that the impact of an RS virus infection is not limited to the sick child. Almost half of the parents (46%) reported taking at least one day off work to care for their child.
Prevention
From autumn 2025, a preventive antibody ‘nirsevimab’ will be added to the National Vaccination Programme in the Netherlands. This will allow babies to be protected against the RS virus during their first winter season. No preventive agent or vaccination is available for children aged 1-5 years. The RSV ComNet study is the first international study on the disease burden of RS virus infections in general practice. The study was funded by Sanofi and AstraZeneca.
Read de publication.
Princess Máxima Center and International Atomic Energy Agency join forces to improve radiotherapy treatments for children
In the presence of Her Majesty Queen Máxima, representatives of the Princess Máxima Center and the International Atomic Energy Agency (IAEA) today signed a four-year partnership aimed at improving practical knowledge on the use of radiotherapy for children with cancer.
MedTech sector launches national growth plan: technology must support Dutch healthcare and structurally strengthen economic growth
The Dutch MedTech sector is presenting an ambitious growth plan today that aims to elevate the Netherlands to the European top by 2035. UMC Utrecht contributed to this plan, and it was co-presented by Carina Hilders (Chair of the UMC Utrecht Executive Board).
Parking rates at Utrecht Science Park to change from 1 January 2026
From 1 January 2026, parking rates at Utrecht Science Park will be adjusted. The Municipality of Utrecht and the owners of the publicly accessible parking facilities at Utrecht Science Park have reached a joint agreement on this.
Wennink plan: Life Sciences and biotechnology are important growth drivers for the earning capacity of the Netherlands
The Dutch Life Sciences and biotechnology sector can make a much larger contribution to the Netherlands’ economic strength. This is shown in a new growth strategy presented today as part of Peter Wennink’s advisory report. The report also highlights Utrecht Science Park as one of the key innovation locations and sources of progress and growth.